Natriuretic peptides' metabolic targets for treatment of cancer

Journal of Investigative Medicine

Volumn 61, Issue 5, 2013, Pages 816-822

  Vesely, David L ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

A catenin; Cardiac hormones; RAS MEK 1 2 ERK 1 2 kinase cascade; Signal transducer and activator of transcription 3; Vascular endothelial growth factor

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA CATENIN; CYCLIC GMP; FRIZZLED PROTEIN; GLYCOPROTEIN; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; HORMONE PRECURSOR; KALIURETIC PEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE RECEPTOR C; PACLITAXEL; PEPTIDE HORMONE; PROTEIN KINASE B; RAS PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 3; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VESSEL DILATOR PEPTIDE; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CANCER THERAPY; DRUG TARGETING; GENE EXPRESSION; HORMONE RECEPTOR INTERACTION; HUMAN; LUNG SMALL CELL CANCER; NONHUMAN; PANCREAS ADENOCARCINOMA; REVIEW; SIGNAL TRANSDUCTION;

MUS; RATTUS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; MYOCARDIUM; NATRIURETIC PEPTIDES; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84881527949     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318292110a     Document Type: Review

References (107)

1. Brenner BM, Ballermann BJ, Gunning M.E., et al Diverse biological actions of atrial natriuretic peptide. Physiol Rev. 1990; 70:665-699.
2. Gardner DG, Kovacic-Milivojevic BK, Garmai M. Molecular biology of the natriuretic peptides. In: Vesely DL, ed. Atrial Natriuretic Peptides. Trivandum, India: Research Signpost; 1997:15-38.
3. Vesely DL. Natriuretic hormones. In: Alpern RJ, Moe OW, Caplan M, eds. Seldin and Giebisch's The Kidney. Physiology and Pathophysiology, edn 5. Amsterdam, The Netherlands: Elsevier/Academic Press; 2013:1241-1281.
4. Yan W, Wu, F, Morser J., et al Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide converting enzyme. Proc Natl Acad Sci U S A. 2000; 97:8525-8529.
5. Vesely DL, Norris JS, Walters J.M., et al Atrial natriuretic prohormone peptides 1-30, 31-67 and 79-98 vasodilate the aorta. Biochem Biophys Res Commun. 1987; 148:1540-1548.
6. 2-terminus are natriuretic and/or kaliuretic Am J Physiol. 1990; 258:F1401-F1408.
7. 2. J Clin Invest. 1992; 89:1411-1417.
8. Benjamin BA, Peterson TV Effects of ProANF (31-67) on sodium excretion in conscious monkeys. Am J Physiol. 1995; 269:R1351-R1355.
9. + reabsorption by ANP 31-67. Clin Exp Pharmacol Physiol. 1995; 22:121-124.
10. Villarreal D, Reams GP, Taraben A, et al Hemodynamic and renal effects of proANF 31-67 in hypertensive rats. Proc Soc Exp Biol Med. 1999; 221:166-170.
11. Dietz JR, Scott DY, Landon C.S., et al Evidence supporting a physiological role for proANP (1-30) in the regulation of renal excretion. Am J Physiol. 2001; 280:R1510-R1517.
12. Vesely DL, Douglass MA, Dietz J.R., et al Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation. 1994; 90:1129-1140.
13. Vesely DL, Douglass MA, Dietz J.R., et al Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab. 1994; 78:1128-1134.
14. Vesely DL, Dietz JR, Parks J.R., et al Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation. 1998; 98:323-329.
15. Vesely DL, Dietz JR, Parks J.R., et al Comparison of vessel dilator and long acting natriuretic peptide in the treatment of congestive heart failure. Am Heart J. 1999:138:625-632.
16. +-ATPase. Renal Physiol. 1983; 6:295-299.
17. +-ATPase of the atrial natriuretic peptides. Endocrinology. 1995; 136:2033-2039.
18. Gower WR J.r., Chiou S, Skolnick K., et al Molecular forms of circulating atrial natriuretic peptides in human plasma and their metabolites. Peptides. 1994; 15:861-867.
19. Vesely BA, Alli AA, Song S, et al Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest. 2005; 35:700-710.
20. Vesely BA, McAfee Q, Gower WR Jr, et al Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest. 2003; 33:998-1005.
21. Gower WR J.r., Vesely BA, Alli A.A., et al Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via guanosine 3',5'-cyclic monophosphate. Int J Gastrointestinal Cancer. 2005; 36:77-87.
22. Vesely BA, Song S, Sanchez-Ramos J, et al Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest. 2005; 35:60-69.
23. Vesely BA, Eichelbaum EJ, Alli A.A., et al Urodilatin and four cardiac hormones decrease human renal carcinoma cell number. Eur J Clin Invest. 2006; 36:810-819.
24. Vesely BA, Song S, Sanchez-Ramos J, et al Five cardiac hormones decrease the number of human small-cell lung cancer cells. Eur J Clin Invest. 2005; 35:388-398.
25. Vesely BA, Fitz SR, Gower WR Jr, et al Vessel dilator: most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of human squamous lung cancer cells. Cancer Lett. 2006; 233:226-231.
26. Vesely BA, Eichelbaum EJ, Alli A.A., et al Four cardiac hormones cause cell death in 81% of human ovarian adenocarcinoma cells. Cancer Therapy. 2007; 5:97-104.
27. Eichelbaum EJ, Vesely BA, Alli A.A., et al Four cardiac hormones decrease up to 82% of human medullary thyroid carcinoma cells within 24 hours. Endocrine. 2006; 30:325-332.
28. Vesely BA, Alli A, Song S., et al Primary malignant tumors of the heart: four cardiovascular hormones decrease the number and DNA synthesis of human angiosarcoma cells. Cardiology. 2006; 105:226-233.
29. Vesely BA, Eichelbaum EJ, Alli A.A., et al Four cardiac hormones cause cell death of melanoma cells and inhibit their DNA synthesis. Am J Med Sci. 2007; 334:342-349.
30. Vesely BA, Eichelbaum EJ, Alli A.A., et al Four cardiac hormones eliminate 4-fold more human glioblastoma cells than green mamba snake peptide. Cancer Lett. 2007; 254:94-101.
31. Rashed HM, Su H, Patel TB Atrial natriuretic peptide inhibits growth of hepatoblastoma (HEP G2) cells by means of activation of clearance receptors. Hepatology. 1993; 17:677-684.
32. Vesely DL, Eichelbaum EJ, Sun Y, et al Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo. 2007; 21:445-452.
33. Pitchumoni CS. Pancreatic disease. In: Stein JH, ed. Internal Medicine. St. Louis, MO: Mosby; 1998:2233-2247.
34. Wolff RA, Crane CH, Li D, et al Neoplasms of the exocrine pancreas. In: Hong WK, Bast RC Jr, Hait WN, et al., eds. Cancer Medicine. London, England: BC Decker Inc; 2010:1144-1171.
35. Eichelbaum EJ, Sun Y, Alli A.A., et al Cardiac hormones and urodilation eliminate up to 86% of human small-cell lung carcinomas in mice. Eur J Clin Invest. 2008; 38:562-570.
36. Vesely DL, Vesely BA, Eichelbaum E.J., et al Four cardiac hormones eliminate up to two-thirds of human breast cancers in athymic mice. In Vivo. 2007; 21:973-978.
37. Lenz A, Sun Y, Eichelbaum E.J., et al Twice weekly intravenous treatment of pancreatic cancer with atrial natriuretic peptide and vessel dilator. In Vivo. 2010; 24:125-130.
38. Chinkers M, Garbers DL, Chang M.S., et al Molecular cloning of a new type of cell surface receptor: a membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature. 1989; 338:78-83.
39. Vesely DL, Cornett LE, McCleod S.L., et al Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67, and 99-126. Peptides. 1990; 11:193-197.
40. Vesely DL, Arnold WC, Winters C.J., et al Increased circulating concentration of the N-terminus of the atrial natriuretic prohormone in persons with pheochromocytomas. J Clin Endocrinol Metab. 1990; 71:1138-1146.
41. Sun Y, Eichelbaum EJ, Skelton WP IV, et al Vessel dilator and kaliuretic peptide inhibit RAS in human prostate cancer cells. Anticancer Res. 2009; 29:971-975.
42. Sun Y, Eichelbaum EJ, Lenz A, et al Atrial natriuretic peptide and long-acting natriuretic peptide inhibit RAS in human prostate cancer cells. Anticancer Res. 2009; 29:1889-1893.
43. Sun Y, Eichelbaum EJ, Lenz A, et al Epidermal growth factor's activation of RAS is inhibited by four cardiac hormones. Eur J Clin Invest. 2010; 40:408-413.
44. Sun Y, Eichelbaum EJ, Lenz A, et al Four cardiac hormones inhibit insulin's mitogenic action via inhibiting RAS. Cancer Therapy. 2009; 7:367-372.
45. McCubrey JA, Steelman LS, Chappell W.H., et al Roles of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007; 1773:1263-1284.
46. Sebolt-Leopold JS. Advances in the development of cancer therapeutics directed against the RAS mitogen-activated protein kinase pathway. Clin Cancer Res. 2008; 14:3651-3656.
47. Crews CM, Alessandrini A, Erikson RL The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science. 1992; 258:478-480.
48. Wu J, Harrison JK, Dent P, et al Identification and characterization of a new mammalian mitogen-activated protein kinase kinase MKK-2. Mol Cell Biol. 1993; 13:4539-4548.
49. Sun Y, Eichelbaum EJ, Wang H, et al Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res. 2007; 27:1387-1392.
50. Sun Y, Eichelbaum EJ, Wang H, et al Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res. 2007; 27:3813-3818.
51. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000; 103:239-252.
52. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000; 103:211-225.
53. Sun Y, Eichelbaum EJ, Wang H, et al Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells. Anticancer Res. 2006; 26:3217-3222.
54. Sun Y, Eichelbaum EJ, Wang H, et al Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells. Anticancer Res. 2006; 26:4143-4148.
55. Sun Y, Eichelbaum EJ, Wang H, et al Insulin and epidermal growth factor activation of ERK 1/2 and DNA synthesis is inhibited by four cardiac hormones. J Cancer Mol. 2007; 3:113-120.
56. Juneja J, Cushman I, Casey PJ G12 Signaling through c-Jun NH 2-terminal kinase promotes breast cancer cell invasion. PLoS One. 2011; 6(11):e26085.
57. Yang YM, Bost F, Charbono W., et al c-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res. 2003; 9:391-401.
58. Bost F, Dean N, McKay R., et al Activation of the Jun kinase/stress-activated protein kinase pathway is required for EGF-autocrine stimulated growth of human A549 lung carcinoma cells. J Biol Chem. 1997; 272:33422-33429.
59. Lane ML, Santana O, Frost C.D., et al Cardiac hormones are c-Jun-N-terminal kinase 2-inhibiting peptides. Anticancer Res. 2012; 32:721-726.
60. Polakis P. Drugging WNT signaling in cancer. EMBO J. 2012; 31:2737-2746.
61. Katoh M. Regulation of WNT3 and WNT3A mRNAs in human cancer cell lines NT2, MCF-7, and MKN45. Int J Oncol. 2002; 20:373-377.
62. Li J, Mizukami Y, Zhang X., et al Oncogenic KRAS stimulates WNT signaling in colon cancer through inhibition of GSK-3beta. Gastroenterology. 2005; 128:1907-1918.
63. Skelton WP I.V., Skelton M, Vesely DL Cardiac hormones are novel inhibitors of Wnt-3a in human cancer cells. Cancer Therapy. 2013; 9:24-29.
64. Lin K, Wang S, Julius M.A., et al The cysteine-rich frizzled domain of Frzb-1 is required and sufficient for modulation of WNT signaling. Proc Natl Acad Sci U S A. 1997; 94:11196-11200.
65. Rattner A, Hsieh JC, Smallwood P.M., et al A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc Natl Acad Sc U S A. 1997; 94:2859-2863.
66. Hirata H, Hinoda Y, Ueno K., et al Role of secreted frizzled-related protein 3 in human renal cell carcinoma. Cancer Res. 2010; 70:1896-1905.
67. Rubin JS, Barshishat-Kupper M, Feroze-Merzoup F, et al Secreted WNT antagonists are tumor suppressors: pro and con. Front Biosci. 2006; 11:2093-2105.
68. Xu YK, Nusse R. The frizzled CRD domain is conserved in diverse proteins including several receptor tyrosine kinases. Curr Biol. 1998; 8:R405-R406.
69. Kawano Y, Kypta R. Secreted antagonists of the WNT signaling pathway. J Cell Sci. 2003; 116:2627-2634.
70. Serafino A, Moroni N, Psaila R., et al Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: evidence of an AKT-mediated cross-talk between acidic tumor microenvironment and WNT-Beta-catenin signaling. Biochim Biophys Acta. 2012; 1822:1004-1018.
71. Skelton WP I.V., Skelton M, Vesely DL Cardiac hormones are potent inhibitors of secreted Frizzled related protein-3 in human cancer cells Exp Ther Med. 2013; 5:475-478.
72. Vivanco I, Sawyers CL The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer. 2002; 2:489-501.
73. Altomare DA, Testa JR Perturbations of the AKT signaling pathway in human cancer. Nat Rev Cancer. 2005; 24:7455-7464.
74. Hay N. The AKT-mTOR tango and its relevance to cancer Cancer Cell. 2005; 8:179-183.
75. Staal SP, Hartley JW, Rowe SP Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc Natl Acad Science U S A. 2007; 74:3065-3067.
76. Roy HK, Olusola BF, Clemens D.L., et al AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis. 2002; 23:201-205.
77. Skelton WP I.V., Skelton M, Vesely DL Inhibition of AKT in human pancreatic, renal and colorectal cancer cells by four cardiac hormones. Anticancer Res. 2013; 33:785-790.
78. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 295:1182-1186.
79. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Rev. 2004; 25:581-611.
80. Hoeben A, Landuyt B, Highley M.S., et al Vascular endothelium growth factor. Pharm Rev. 2004; 56:549-580.
81. Doanes AM, Hegland DD, Sethi R, et al VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases. Biochem Biophys Res Commun. 1999; 255:545-548.
82. Meadows KN, Bryant P, Pumiglia K. Vascular endothelial growth factor induction of the angiogenic phenotype requires RAS activation. J Biol Chem. 2001; 276:49289-49298.
83. Byrne AM, Bouchier-Hayes DJ, Harmey JH Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005; 9:777-794.
84. Wang K, Jiang YZ, Chen D.B., et al Hypoxia enhances FGF-2 and VEGF stimulated human placental artery endothelial cell proliferation: roles of MEK-1/2/ERK1-2 and PI3K/AKT1 pathways. Placenta. 2009; 30:1045-1051.
85. Gupta I, Kshirsagar S, Li W., et al VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res. 1999; 247:495-504.
86. Breslin JW, Pappas PJ, Cerveira J.J., et al VEGF increases endothelial permeability by separate signaling pathways involving ERK 1/2 and nitric oxide. Am J Physiol. 2003; 284:H92-H100.
87. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist. 2000; 5:S3-S10.
88. Nguyen JP, Frost CD, Lane M.L., et al Novel dual inhibitors of vascular endothelial growth factor and the VEGFR2 Receptor. Eur J Clin Invest. 2012; 42:1061-1067.
89. Zhang X, Gaspard JP, Chung DC Regulation of vascular endothelial growth factor by the WNT and KRAS pathways in colonic neoplasia. Cancer Res. 2001; 61:6050-6054.
90. Lowe AW, Olsen M, Hao Y., et al Gene expression patterns in pancreatic tumors, cells and tissues. PLoS One. 2007; 2:e323.
91. Heiser PW, Cano DA, Landsman L, et al Stabilization of beta-catenin induces pancreas tumor formation. Gastroenterology. 2008; 135:1288-1300.
92. Mirabelli-Primidahl L., Gryfe R, Kim H., et al Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res. 1999; 59:3346-3351.
93. Bienz M, Clevers H. Linking colorectal cancer to WNT signaling. Cell. 2000; 103:311-320.
94. Bilim V, Kawasaki T, Katagiri A., et al Altered expression of beta-catenin in renal cell cancer and transitional cell cancer with the absence of beta-catenin gene mutations. Clin Cancer Res. 2000; 6:460-466.
95. Maiti S, Alam R, Amos C.I., et al Frequent association of beta-catenin and WTI mutations in Wilms tumors. Cancer Res. 2000; 60:6288-6292.
96. Morin PJ. Beta-catenin signaling and cancer. Bioassays. 1999; 21:1021-1030.
97. Ebert MP, Yu J, Hoffamann J., et al Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol. 2003; 21:1708-1714.
98. Abbosh PH, Nephew KP Multiple signaling pathways converge on beta-catenin in thyroid cancer. Thyroid. 2005; 15:551-561.
99. Mann B, Gelos M, Siedow A., et al Target genes of A-catenin-T cell factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A. 1999; 96:1603-1608.
100. Schindler C, Shuai K, Prezioso V.R., et al Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science. 1992; 257:809-813.
101. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2002; 2:740-749.
102. Yu H, Jove R. The STATs of cancer: new molecular targets come of age. Nat Rev Cancer. 2004; 4:450-456.
103. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2002; 19:2468-2473.
104. Grandis J, Drenning SD, Chakraborty A, et al Requirement of STAT3 but not STAT1 activation for epidermal growth factor receptor-medicated cell growth in vitro. J Clin Invest. 1998; 102:1385-1392.
105. Song L, Turkson J, Karras J.G., et al Activation of STAT3 by receptor tyrosine kinases and cytokinases regulates survival in human non-small-cell carcinoma cells. Oncogene. 2003; 22:4150-4165.
106. Duan Z, Foster R, Bell D.A., et al Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res. 2006; 12:5055-5063.
107. Lane ML, Frost CD, Nguyen J.P., et al Potent selective inhibition of STAT3 versus STAT1 by cardiac hormones. Mol Cell Biochem. 2012; 371:209-215.